Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of trastuzumab deruxtecan T-DXd combined with rilvegostomig, and T-DXd alone, compared with the standard treatment of gemcitabine, cisplatin, and durvalumab for patients with advanced, untreated HER2-expressing biliary tract cancer. This Phase 3 study focuses on patients with locally advanced or metastatic disease, aiming to compare overall survival and other outcomes across different treatment groups. Participants are assigned to one of three groups one receiving T-DXd and rilvegostomig together, another receiving T-DXd alone, and a third receiving the standard care of gemcitabine, cisplatin, and durvalumab. All treatments are given by intravenous infusion. The study includes an initial safety run-in phase followed by a randomized portion where patients receive assigned treatments until disease progression or other criteria are met. The study is estimated to continue for up to 50 months after the first patient is randomized. During the trial, participants will have tumor samples collected, and their disease will be monitored through imaging and clinical assessments. Researchers will evaluate safety, tolerability, overall survival, progression-free survival, response rates, and patient-reported outcomes like side effects and physical functioning. Blood samples will be taken to study drug levels and immune responses. The study plans to follow participants for long-term outcomes and side effects, with regular visits scheduled throughout the study duration.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.